One bigquestion: would the limited data Sarepta has so far collected from avery small clinical trial of its drug eteplirsen, a treatment for Duchenne muscular dystrophy that is caused by avery specific type of mutation, be enough to warrant filing with the Food and Drug Administration and perhaps even gain approval?